Venous thromboembolism with inflammatory bowel disease.
Venous thrombosis and thromboembolism appear to be increased in patients with inflammatory bowel disease. Although several acquired and genetic risk factors are known, about half that develop a thromboembolic event have no identifiable risk factor. Control of the inflammatory process is thought to be the key factor in risk reduction for thrombotic events. Prophylactic use of anticoagulants is not universally recommended, but possible use should be reviewed in an individual patient after evaluation of the risks, such as hemorrhage, compared to potential benefits. Particular consideration should be given if there has been a prior thrombotic event, if hospitalization will require surgery, or if an underlying coagulation disorder is present.
Freeman
Hugh James
HJ
Department of Medicine, Gastroenterology, University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 1W5, Canada. hugfree@shaw.ca
D005165:Factor V / Q000235:genetics; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000235:genetics / Q000628:therapy; D009154:Mutation; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control / Q000628:therapy
C095381:factor V Leiden; D005165:Factor V